205 related articles for article (PubMed ID: 15626895)
1. Autoantibodies against the bactericidal/permeability-increasing protein from inflammatory bowel disease patients can impair the antibiotic activity of bactericidal/permeability-increasing protein.
Schinke S; Fellermann K; Herlyn K; Reichel PH; Fundke R; Stange EF; Gross WL; Schultz H
Inflamm Bowel Dis; 2004 Nov; 10(6):763-70. PubMed ID: 15626895
[TBL] [Abstract][Full Text] [Related]
2. Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease.
Walmsley RS; Zhao MH; Hamilton MI; Brownlee A; Chapman P; Pounder RE; Wakefield AJ; Lockwood CM
Gut; 1997 Jan; 40(1):105-9. PubMed ID: 9155585
[TBL] [Abstract][Full Text] [Related]
3. BPI-ANCA of pediatric cystic fibrosis patients can impair BPI-mediated killing of E. coli DH5alpha in vitro.
Schultz H; Schinke S; Mosler K; Herlyn K; Schuster A; Gross WL
Pediatr Pulmonol; 2004 Feb; 37(2):158-64. PubMed ID: 14730661
[TBL] [Abstract][Full Text] [Related]
4. Recognition of bactericidal/permeability-increasing protein by perinuclear anti-neutrophil cytoplasmic antibody-positive sera from ulcerative colitis patients: prevalence and clinical significance.
Vecchi M; Sinico A; Bianchi MB; Radice A; Gionchetti P; Campieri M; de Franchis R
Scand J Gastroenterol; 1998 Dec; 33(12):1284-8. PubMed ID: 9930392
[TBL] [Abstract][Full Text] [Related]
5. [Bactericidal permeability increasing protein (BPI-ANCA marked chronic inflammatory bowel diseases and hepatobiliary diseases].
Schnabel A; Csernok E; Schultz H; Stoffel M; Herzberg C; Carroll SF; Gross WL
Med Klin (Munich); 1997 Jul; 92(7):389-93. PubMed ID: 9324622
[TBL] [Abstract][Full Text] [Related]
6. Anti-neutrophil cytoplasmic autoantibodies (ANCA) to bactericidal/permeability-increasing (BPI) protein recognize the carboxyl terminal domain.
Dunn AC; Walmsley RS; Dedrick RL; Wakefield AJ; Lockwood CM
J Infect; 1999 Jul; 39(1):81-7. PubMed ID: 10468134
[TBL] [Abstract][Full Text] [Related]
7. ANCA against bactericidal/permeability-increasing protein, azurocidin, calprotectin and defensins in rheumatic and infectious diseases: prevalence and clinical associations.
Schultz H; Csernok E; Herlyn K; Reichel PH; Moosig F; Cornely OA; Fagerhol MK; Gross WL
Clin Exp Rheumatol; 2003; 21(6 Suppl 32):S117-20. PubMed ID: 14740437
[TBL] [Abstract][Full Text] [Related]
8. Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis.
Zhao MH; Jones SJ; Lockwood CM
Clin Exp Immunol; 1995 Jan; 99(1):49-56. PubMed ID: 7813109
[TBL] [Abstract][Full Text] [Related]
9. Frequency of anti-bactericidal/permeability-increasing protein (BPI) and anti-azurocidin in patients with renal disease.
Yang JJ; Tuttle R; Falk RJ; Jennette JC
Clin Exp Immunol; 1996 Jul; 105(1):125-31. PubMed ID: 8697620
[TBL] [Abstract][Full Text] [Related]
10. BPI-ANCA in transporter associated with antigen presentation (TAP) deficiency: possible role in susceptibility to Gram-negative bacterial infections.
Schultz H; Schinke S; Weiss J; Cerundolo V; Gross WL; Gadola S
Clin Exp Immunol; 2003 Aug; 133(2):252-9. PubMed ID: 12869032
[TBL] [Abstract][Full Text] [Related]
11. Clinical associations and characterisation of antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein and azurocidin.
Cooper T; Savige J; Nassis L; Paspaliaris B; Neeson P; Neil J; Knight KR; Daskalakis M; Doery JC
Rheumatol Int; 2000; 19(4):129-36. PubMed ID: 10836522
[TBL] [Abstract][Full Text] [Related]
12. Detection rate and antigenic specificities of antineutrophil cytoplasmic antibodies in chinese patients with clinically suspected vasculitis.
Xin G; Zhao MH; Wang HY
Clin Diagn Lab Immunol; 2004 May; 11(3):559-62. PubMed ID: 15138182
[TBL] [Abstract][Full Text] [Related]
13. Use of native and recombinant bactericidal/permeability-increasing proteins (BPI) as antigens for detection of BPI-ANCA.
Schultz H; Csernok E; Johnston TW; Lockwood CM; Gross WL
J Immunol Methods; 1997 Jul; 205(2):127-33. PubMed ID: 9294593
[TBL] [Abstract][Full Text] [Related]
14. Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis.
Zhao MH; Jayne DR; Ardiles LG; Culley F; Hodson ME; Lockwood CM
QJM; 1996 Apr; 89(4):259-65. PubMed ID: 8733512
[TBL] [Abstract][Full Text] [Related]
15. Anti-neutrophil cytoplasmic antibodies directed against the bactericidal/permeability-increasing protein (BPI) in pediatric cystic fibrosis patients do not recognize N-terminal regions important for the anti-microbial and lipopolysaccharide-binding activity of BPI.
Schultz H; Csernok E; Schuster A; Schmitz TS; Ernst M; Gross WL
Pediatr Allergy Immunol; 2000 May; 11(2):64-70. PubMed ID: 10893006
[TBL] [Abstract][Full Text] [Related]
16. BPI-ANCA is found in reactive arthritis caused by Yersinia and Salmonella infection and recognise exclusively the C-terminal part of the BPI molecule.
Schultz H; Csernok E; Nikkari S; Toivanen P; Toivanen A; Gross WL
Scand J Rheumatol; 2000; 29(4):226-31. PubMed ID: 11028843
[TBL] [Abstract][Full Text] [Related]
17. Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease.
Mahadeva R; Dunn AC; Westerbeek RC; Sharples L; Whitehouse DB; Carroll NR; Ross-Russell RI; Webb AK; Bilton D; Lomas DA; Lockwood CM
Clin Exp Immunol; 1999 Sep; 117(3):561-7. PubMed ID: 10469063
[TBL] [Abstract][Full Text] [Related]
18. Anti-neutrophil cytoplasmic autoantibodies against bactericidal/permeability-increasing protein in patients with rheumatoid arthritis and their correlation with bronchial involvement.
Wada Y; Kuroda T; Murasawa A; Nakano M; Narita I
Mod Rheumatol; 2010 Jun; 20(3):252-6. PubMed ID: 20107854
[TBL] [Abstract][Full Text] [Related]
19. Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeability-increasing protein.
Levy O; Martin S; Eichenwald E; Ganz T; Valore E; Carroll SF; Lee K; Goldmann D; Thorne GM
Pediatrics; 1999 Dec; 104(6):1327-33. PubMed ID: 10585984
[TBL] [Abstract][Full Text] [Related]
20. ANCA against the bactericidal/permeability increasing protein (BPI-ANCA) can compromise the antibiotic function of BPI in a Wegener's granulomatosis patient.
Schultz H; Heintz H; van Zandbergen G; Ullrich S; Reinhold-Keller E; Gross WL
Clin Exp Rheumatol; 2003; 21(6):763-6. PubMed ID: 14740457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
